CDXS Codexis, Inc.
Codexis, Inc. (CDXS) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.8% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Codexis, Inc.
Codexis Inc is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. It has recently started to use its technology to develop biocatalysts for use in the fine chemicals markets.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.